Location History:
- Watertown, MA (US) (2022)
- Newton, MA (US) (2017 - 2024)
Company Filing History:
5 out of 1,373 
3 out of 4,455 
1 out of 1,036 
Years Active: 2017-2025
Title: Steven A Greenberg: Innovator in Therapeutic Antibodies and Cancer Treatment
Introduction
Steven A Greenberg, based in Newton, MA, is a notable inventor with a focus on innovative therapeutic solutions. With four patents to his name, his contributions significantly enhance the field of biomedical research and cancer treatment.
Latest Patents
Among his most recent inventions are the "Interferon beta antibodies and uses thereof," which involves antibodies specifically designed to bind to interferon beta (IFNβ). This technology has potential therapeutic and diagnostic applications, facilitating advancements in medical treatments. Another groundbreaking patent is the "KLRG1 antagonist signaling therapy." This method treats various types of cancers, including melanoma and lung cancer, by utilizing killer cell lectin-like receptor G1 (KLRG1) ligand binding agents. By disrupting KLRG1 signaling, this approach activates cytotoxic T and NK cells, offering new hope to patients with severe cancers.
Career Highlights
Steven has had a distinguished career, contributing to significant institutions such as the Brigham and Women's Hospital, Inc. and Pfizer Corporation. His work is characterized by a commitment to advancing therapeutic methods aimed at improving patient outcomes.
Collaborations
Throughout his career, Steven has collaborated with talented individuals including Stefano V Gulla and Christine Huard. These partnerships have been instrumental in refining his innovative ideas and bringing them to fruition in the field of medical science.
Conclusion
Steven A Greenberg's contributions to medicine through his patents and collaborations underscore his role as an impactful inventor. His work continues to inspire advances in therapies for cancer and antibody-based treatments, highlighting the critical intersection of innovation and human health.